OOIR: Observatory of International Research

Papers

(The median citation count of Annual Review of Cancer Biology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Immune Cell Metabolism and Immuno-Oncology	93
YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer	63
Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond	33
Distinct Essentiality of the Mitochondrial Respiratory Chain in Proliferating Cells In Vivo	31
lncRNAs as Targetable Nodes of Oncogenic Networks Underlying Cancer Progression and Therapy Resistance	31
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy	30
Lessons from 3D Reconstruction of Cancer	28
Mitochondria, OXPHOS, and Cancer Progression: A Modular View	28
Natural and Engineered Cytokines as Cancer Therapeutics	27
They Contain Multitudes: The Diverse Roles of CD4+ T Cells in Cancer Immunity	26
Allogeneic CAR T Cell Therapy for Cancer	26
Cancer Genomic Rearrangements and Copy Number Alterations from Errors in Cell Division	25
Beyond Mice and Men: Alternative Vertebrate and Invertebrate Models in Cancer Biology	23
Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?	22
Caught in a Web: Emerging Roles of Neutrophil Extracellular Traps in Cancer	20
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies	19
Road Map to Defeat Pancreatic Cancer	19
Cancer Dependency Map: Past and Present	17
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches	15
Engineering Cancer with Next-Generation Genome Editing Tools	13
Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy	13
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been	12
An Erratic Path Toward Discovery	12
The Effects of Clonal Heterogeneity on Cancer Immunosurveillance	12
Strategies for Heating Up Cold Tumors to Boost Immunotherapies	11

Extrachromosomal DNA: Biogenesis and Functions in Cancer	11
Targeting Minimal Residual Disease	11
Glycosylation in Cancer: From Functional Roles to Therapeutic Implications	11
Reinventing Radiobiology in the Light of FLASH Radiotherapy	11
Engineering the Immune Microenvironment into Organoid Models	11
RB1, Cancer Lineage Plasticity, and Therapeutic Resistance	10
Mechanism of Action of PARP Inhibitors	10
Antibody–Drug Conjugates: The Past, Present and Future	10
Metabolic Rewiring During Metastasis: The Interplay Between the Environment and the Host	9
Novel Mouse Models for Cancer Immunology	9
	8
Metabolic Reprogramming in Cancer Cachexia	8
Next-Generation Therapies for Multiple Myeloma	8
Emerging Mechanisms of Lactate Regulation of Biological Processes	8
Not All Carcinogens Are Directly Mutagenic: A Holistic View of the Environmental Exposure–Cancer Connection	8
Cancer Dormancy as a Collective Phenomenon Across Scales in Length and Time: Biological Observations and Advanced 3D Bioengineered Models	8
DNA-Encoded Libraries in Cancer Research: Recent Landmarks and Future Promises	7
Lineage-Specific Transcription Factors in Carcinogenesis	7
Targeting BET Bromodomains in Cancer	7
Awakening the Genome: CRISPR Activation to Unravel the Origin and Vulnerabilities of Cancer	4
The Metabolic Relationship Between Viral Infection and Cancer	3
Germline Predisposition to Hematopoietic Malignancies: An Overview	3
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy	3
TRACERx as an Optimized Paradigm for Understanding Cancer Evolution	3
	3
New Tools for Lineage Tracing in Cancer In Vivo	3
	3
Development of PROTAC Degrader Drugs for Cancer	3
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins	3